Final analysis of Covaxin efficacy out; vaccine 65.2% effective against Delta variant
The Hindu
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases
Bharat Biotech's has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and65.2 per cent . The company on Saturday, July 3, 2021, said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. Also read:More Related News

The Centre has rejected reports that the definition of the Aravalli hills was changed to permit large-scale mining, citing a Supreme Court-ordered freeze on new leases. It said a court-approved framework will bring over 90% of the Aravalli region under protected areas and strengthen safeguards against illegal mining. The clarification follows controversy over the “100-metre” criterion used to define hills across states.












